Lactobacillus Crispatus

Your vagina has a dominant species, and which one it is matters more than most people realize. When Lactobacillus crispatus runs the show, the local environment stays acidic, low in inflammation, and resistant to a long list of infections and pregnancy complications. When it gets replaced by other bacteria, even other lactobacilli, the risk profile shifts.

Measuring Lactobacillus crispatus on a vaginal swab tells you which version of the ecosystem you have. It is not just about whether you have an active infection. It is about whether your body has the microbial defense system that consistently links to lower rates of bacterial vaginosis, urinary tract infections, sexually transmitted infections, and preterm birth.

What This Test Actually Captures

Lactobacillus crispatus (often shortened to L. crispatus) is a lactic acid producing bacterium that lives on the lining of the vagina and cervix. It uses glycogen from vaginal cells as fuel and releases lactic acid, which keeps the local pH low and inhibits other microbes. When it dominates, scientists classify the community as community state type I, considered the most protective configuration.

A vaginal swab quantifies how much L. crispatus is present, usually by molecular methods such as quantitative PCR. The number reflects three connected things: how Lactobacillus dominant your microbiome is, how acidic the environment likely is, and how low the local inflammation tends to run. Other Lactobacillus species, especially L. iners, are sometimes lumped together with L. crispatus in casual conversation, but they behave very differently. L. iners is less protective and often shows up during transitional or unstable states.

Bacterial Vaginosis and Vaginal Dysbiosis

Bacterial vaginosis (BV) is an imbalance where protective lactobacilli are replaced by a mix of anaerobic bacteria. L. crispatus is one of the strongest single markers of whether BV is present, though research suggests it works best as part of a multi-marker panel rather than as a standalone test. In one study using low L. crispatus as a marker for BV, sensitivity was reported around 95.9% and specificity around 72.3%, though most studies find that L. crispatus alone is less accurate than panels that include additional markers.

When L. crispatus is measured alongside Gardnerella vaginalis, a bacterium that overgrows in BV, accuracy climbs further: combinations of L. crispatus with G. vaginalis or Fannyhessea vaginae have achieved over 99% sensitivity and 97% specificity. The ratio of L. crispatus to Gardnerella vaginalis (expressed as a log score) reaches sensitivity of 93.5% to 97.3% and specificity of 92.5% to 97.2% across development and validation cohorts. What this means for you: a low L. crispatus reading, especially with high Gardnerella, is one of the most reliable molecular signals of BV available.

Urinary Tract Infections

The vagina and bladder share microbes through a short anatomical bridge. Vaginal L. crispatus levels predict bladder colonization on paired swab and urine samples in a study of 93 women, supporting what researchers call a vagina to bladder axis. In a randomized phase 2 trial of 100 premenopausal women with recurrent urinary tract infections, recurrent UTI occurred in 15% of women receiving intravaginal L. crispatus (LACTIN-V) compared with 27% of those given placebo (relative risk 0.5, 95% CI 0.2 to 1.2). The overall difference did not reach statistical significance, but a significant reduction was seen in the subgroup of women who achieved high-level vaginal colonization.

Sexually Transmitted Infections and HIV

L. crispatus dominance is consistently linked to lower risk of acquiring or sustaining sexually transmitted infections. In a meta-analysis of cervicovaginal lactobacilli, L. crispatus was identified as the species most strongly associated with reduced high-risk HPV infection, cervical intraepithelial neoplasia, and cervical cancer. In a cohort of 688 young South African women, those with polymicrobial vaginal communities had about 7 times higher HIV acquisition risk than those with L. crispatus dominant microbiomes (hazard ratio 7.19, 95% CI 2.11 to 24.5). A separate study found diverse anaerobe-dominant communities carried roughly a 4-fold increase in HIV acquisition risk.

Across studies, L. crispatus dominant communities also have lower rates of chlamydia compared with L. iners dominant ones, with L. iners dominant microbiotas showing about 3.4-fold higher odds of chlamydia in meta-analysis. The protective effect is biological as well as statistical: L. crispatus dominant secretions show stronger inhibition of E. coli growth in laboratory tests, and women with L. crispatus dominant microbiomes have higher bacterial IgA coating (an antibody response that may help maintain the stable state).

Pregnancy and Preterm Birth

Pregnancy hormones favor L. crispatus. Rising estradiol and progesterone are associated with increasing L. crispatus abundance, and many women shift to non-Lactobacillus profiles after delivery. In a third-trimester cohort of over 1,800 women, presence of L. crispatus was strongly inversely associated with group B Streptococcus (GBS) colonization, with roughly half the odds compared with women without it (odds ratio approximately 0.5). GBS is a major cause of newborn infection, so this is one of the few markers that links a vaginal microbe directly to a neonatal risk.

A network meta-analysis on preterm birth found that women with a low-lactobacilli vaginal microbiome are at increased risk (odds ratio around 1.69), while those with an L. crispatus dominant community are at the lowest risk. A study of 824 women showed that lower L. crispatus abundance increased the risk of spontaneous preterm birth, with patterns that differed by race and were obscured by vaginal douching. In another cohort of 223 Korean women, having Lactobacillus abundance below about 90% was associated with preterm birth risk.

Pregnancy Loss and Fertility

In a nested case-control study of women with recurrent pregnancy loss, L. crispatus was less abundant and Gardnerella more abundant in both endometrial and vaginal samples compared with controls. A systematic review and meta-analysis on female infertility found that a high-Lactobacillus vaginal microbiota was negatively associated with infertility, though the specific mechanisms are still being mapped.

Candida and Yeast

L. crispatus dominant microbiomes are less likely to harbor Candida than L. iners dominant or diverse communities. In a study of 255 nonpregnant women, L. iners dominant communities were about 2.85 times more likely to harbor Candida than L. crispatus dominant communities. This is consistent with stronger lactic acid production and direct inhibitory activity from L. crispatus, which translates to fewer favorable conditions for yeast overgrowth.

Why a Single Reading Is Not Enough

The vaginal microbiome shifts with the menstrual cycle, sexual activity, pregnancy, and contraceptive method. A single low reading might capture a temporary dip rather than a stable pattern, and a single high reading does not guarantee the state will persist. Tracking your trend matters more than chasing one number.

Get a baseline, then retest in 3 to 6 months if you are making changes such as starting or stopping hormonal contraception, treating BV, using a probiotic, or planning pregnancy. After that, at least annual testing makes sense if you have a history of recurrent BV, urinary tract infections, sexually transmitted infections, preterm birth, or pregnancy loss. During pregnancy, more frequent testing in the first and third trimesters can help you and your clinician catch transitions that are linked to preterm birth risk. Routine vaginal microbiome monitoring is not currently part of professional society guidelines, so results are best interpreted with a clinician familiar with this research.

When Results Can Be Misleading

A handful of factors can shift the reading without reflecting a stable change in your microbiome. Keep these in mind when interpreting a single result:

• Recent sex: in a study of 426 African women, recent sexual exposure was linked to lower prevalence of protective Lactobacillus species including L. crispatus.
• Menstrual cycle phase: levels shift across the cycle and may be temporarily lower around menses.
• Recent antibiotic use: metronidazole reduces BV-associated bacteria but does not raise L. crispatus in the short term, so a swab taken just after treatment may show low levels of everything.
• Sample collection technique: contamination from skin or improper placement of the swab can distort molecular counts.

Decision Pathway for Out-of-Pattern Results

If your L. crispatus is low and you have symptoms (unusual discharge, odor, itching, burning, or recurrent infections), the most useful next step is a full BV workup that includes Gardnerella vaginalis, Atopobium (Fannyhessea) vaginae, and other anaerobes, plus testing for sexually transmitted infections and yeast. If you are pregnant or planning pregnancy, a low result is worth a conversation with your obstetrician about repeat testing and whether your individual risk profile warrants extra monitoring.

If your L. crispatus is low but you have no symptoms, the value is in trending the number and identifying modifiable factors such as condom use, douching, or recent antibiotic exposure. A gynecologist or reproductive health specialist familiar with vaginal microbiome science can help interpret results in the context of your overall picture. If you have a history of recurrent BV, recurrent UTIs, preterm birth, or recurrent pregnancy loss, low L. crispatus is a signal to investigate companion tests rather than wait.